[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593013":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":10,"id":55,"slug":10,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Université Catholique de Louvain","OTHER",[8,12,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":10},"juvenile idiopathic arthritis (JIA)",null,"aged \\\u003C= 16 y.o. recent diagnosis of JIA and DMARDs treatment-naive patients; aged \\\u003C18 y.o. recent diagnosis of JIA",{"label":13,"type":10,"description":14,"interventionNames":10},"rheumatoid arthritis (RA)","aged =\\>18; =\\\u003C 50 y.o. recent diagnosis of RA and DMARDs treatment-naive patients",{"label":16,"type":10,"description":17,"interventionNames":10},"diffuse systemic sclerosis (dSS)","aged =\\>18; =\\\u003C 50 y.o. recent diagnosis of dSS and DMARDs treatment-naive patients",{"label":19,"type":10,"description":20,"interventionNames":10},"seronegative arthritis (UA)","aged =\\>18; =\\\u003C 50 y.o. recent diagnosis of UA and DMARDs treatment-naive patients",{"label":22,"type":10,"description":23,"interventionNames":10},"systemic lupus erythematosus (SLE)","aged =\\>18; =\\\u003C 50 y.o. recent diagnosis of SLE and DMARDs treatment-naive patients",[25],{"name":26,"affiliation":27,"role":28},"Patrick Durez, Pr","UCLouvain - IREC","STUDY_DIRECTOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Patrick Durez","CONTACT","+32 02 764 53 89","patrick.durez@uclouvain.be",[36],{"facility":37,"status":38,"city":39,"state":10,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"UCLouvain","RECRUITING","Brussels","1200","Belgium",{"type":43,"coordinates":44},"Point",[45,46],4.34878,50.85045,{"lat":46,"lon":45},[49,50],{"name":31,"role":32,"phone":10,"phoneExt":10,"email":34},{"name":51,"role":32,"phone":10,"phoneExt":10,"email":52},"Tatiana Sokolova","tatiana.sokolova@uclouvain.be",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100593013",false,"NCT07000916","Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults. Optimization of Clinical Response, Remission, Quality of Life and Analysis of Prognostic Markers","Inclusion Criteria:\n\n* Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative \u002F psoriatic \u002F undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria).\n* Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.\n\nExclusion Criteria:\n\n* Treated for \\> 3 months\n* \\> 50 years old","ALL","2 Years","50 Years",{"count":65,"type":66},1000,"ESTIMATED","10 Years","OBSERVATIONAL","Population:\n\nJuvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative \u002F psoriatic \u002F undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).\n\nNaïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.\n\nThese 5 cohorts will be subject to standardized clinical monitoring.",[71,72,73,74,75,76],"Juvenile Idiopathic Arthritis","Rheumatoid Arthritis","Psoriatic Arthritis","Systemic Lupus Erythematosus","Diffuse Systemic Sclerosis","Seronegative Arthritis","2025-05-22",{"date":79,"type":80},"2025-06-03","ACTUAL",{"date":82,"type":80},"2013-09-11",{"date":84,"type":66},"2028-03-31",{"name":5,"class":6},1]